Acceleron: Merck's blood vessel disorder drug succeeds in late-stage study

Merck & Co said a therapy it gained through the drugmaker's $11.5 billion acquisition of Acceleron Pharma last year met the main goal of a late-stage study in patients with a progressive blood vessel disorder.